CARE for AIDS Revenue and Competitors
Estimated Revenue & Valuation
- CARE for AIDS's estimated annual revenue is currently $35M per year.
- CARE for AIDS's estimated revenue per employee is $257,353
Employee Data
- CARE for AIDS has 136 Employees.
- CARE for AIDS grew their employee count by -2% last year.
CARE for AIDS's People
Name | Title | Email/Phone |
---|---|---|
1 | Senior Donor Engagement Director | Reveal Email/Phone |
CARE for AIDS Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 59 | 34% | N/A | N/A |
#2 | $15M | 37 | 6% | N/A | N/A |
#3 | $3.5M | 10 | N/A | N/A | N/A |
#4 | $3.5M | 32 | 7% | N/A | N/A |
#5 | $300M | 1833 | 7% | N/A | N/A |
#6 | $35M | 83 | -3% | N/A | N/A |
#7 | N/A | 42 | 11% | N/A | N/A |
#8 | $7.5M | 60 | 2% | N/A | N/A |
#9 | N/A | 215 | 38% | N/A | N/A |
#10 | $35M | 84 | 9% | N/A | N/A |
What Is CARE for AIDS?
CARE for AIDS exists to mobilize the church in caring, both physically and spiritually, for families affected by HIV/AIDS in East Africa.
keywords:N/AN/A
Total Funding
136
Number of Employees
$35M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CARE for AIDS News
2022-04-20 - Over 17 lakh people contracted HIV in India in last 10 years by unprotected
sex: RTI reply
HIV has no effective treatment. However, it can be managed with proper medical care. Satish Koul, Director, Internal Medicine,...
2022-04-19 - Rose Walton was a pioneering HIV/AIDS advocate with a great love story
Walton died earlier this month at her Sunset Beach home. She was 85. A pioneering figure in HIV/AIDS care and advocacy, Walton did much of her...
2022-04-17 - New guidelines from WHO recommend a simpler, safer ...
... amphotericin B as part of the preferred induction regimen for the treatment of cryptococcal meningitis in people living with HIV.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $39.4M | 136 | 5% | N/A |
#2 | $36.7M | 136 | 4% | N/A |
#3 | $23.1M | 136 | 5% | N/A |
#4 | N/A | 136 | N/A | N/A |
#5 | $19.7M | 136 | 10% | N/A |